Related Experiment Video

Updated: Jul 10, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Mometasone furoate dry-powder inhaler for the control of persistent asthma

Anthony D'Urzo1

  • 1Primary Care Lung Clinic, 1670 Dufferin Street (Suite 107), Toronto, Ontario, Canada. tonydurzo@sympatico.ca

Expert Opinion on Pharmacotherapy
|October 25, 2007
PubMed

Insights

Mometasone furoate dry-powder inhaler (MF-DPI) offers effective asthma control with a convenient once-daily regimen. This inhaled corticosteroid (ICS) shows significant lung function improvement and symptom relief in patients with persistent asthma.

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Mometasone furoate dry-powder inhaler (MF-DPI) is an inhaled corticosteroid (ICS) for persistent asthma treatment in patients aged 12 years and older.
  • MF-DPI exhibits low systemic bioavailability and high glucocorticoid receptor affinity, influencing asthma pathogenesis mediators.
  • Unlike other ICSs, MF-DPI is approved for once-daily in the afternoon (q.d. PM) initiation.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Mometasone furoate dry-powder inhaler (MF-DPI) in managing persistent asthma.

Main Methods:

  • Studies assessed MF-DPI 200 or 400 microg q.d. PM treatment in patients with mild, moderate, or severe asthma.
  • Comparative efficacy of MF-DPI 400 microg q.d. PM was evaluated against fluticasone propionate, beclometasone dipropionate, and budesonide.

Main Results:

  • MF-DPI 200 or 400 microg q.d. PM significantly improved lung function and asthma symptom control.
  • MF-DPI 400 microg q.d. PM demonstrated equivalence to fluticasone propionate 250 microg b.i.d. and beclometasone dipropionate 168 microg b.i.d.
  • MF-DPI 400 microg q.d. PM was more efficacious than budesonide 400 microg (b.i.d. or q.d.).

Conclusions:

  • MF-DPI provides significant benefits for persistent asthma management, including improved lung function and symptom control.
  • The once-daily PM regimen of MF-DPI is effective and comparable to other ICS treatments.
  • MF-DPI is well-tolerated with minimal impact on the hypothalamic-pituitary-adrenal axis.

More Related Videos

Intratracheal Administration of Dry Powder Formulation in Mice07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...